ROS1 and glioblastoma: More recently, Coccè et al. identified these fusion genes in a congenital glioblastoma in a 2-month-old boy, suggesting that ROS1 rearrangement could act as a key oncogenic driver in a specifical subset of GBM [48], in addition to the well-known GOPC-ROS1 fusion, largely reported in the congenital glioblastoma series [49,50].